1. Introduction {#s1}
===============

Cardiac resynchronization therapy (CRT) improves symptoms, reduces heart failure (HF) hospitalization, and improves survival in patients with symptomatic HF, impaired left ventricular ejection fraction (LVEF) and prolonged QRS duration.[@b1]--[@b6] Although the prevalence of HF increases significantly with age from 2%--3% in the general population to 10%--20% among those aged greater than elderly patients have been underrepresented in the seminal trials assessing the safety and efficacy of CRT.[@b7] The median age of patients enrolled in the comparison of medical therapy, pacing and defibrillation in heart failure (COMPANION),[@b3] cardiac resynchronization--heart failure (CARE-HF),[@b8] and cardiac resynchronization in chronic heart failure (MIRACLE)[@b1] trials was between 64 and 68 years old. Therefore, discordance exists between the burgeoning heart failure epidemic among elderly patients and the robustness of clinical evidence to support the use of CRT in this population. Although several studies have demonstrated comparable improvements in New York Heart Association (NYHA) class and parameters of left ventricular reverse remodeling, usually measured at 6--12 months post-implant, between elder and younger recipients of CRT,[@b9]--[@b13] data on longer-term clinical outcomes, including rates of all-cause mortality, are more discordant. Whereas some studies have suggested that survival in octogenarians after CRT is worse than that among younger recipients,[@b14] others have demonstrated comparable survival between age groups.[@b15]

Given the substantial costs associated with device implant and follow-up, defining evidence-based strategies for HF management among elderly patients is imperative. In order to better define outcomes of CRT in octogenarians, particularly with regard to all-cause mortality, we compared outcomes of consecutive octogenarians undergoing CRT at our institution to a control cohort of younger CRT recipients during the same time period.

2. Methods {#s2}
==========

2.1. Study population {#s2a}
---------------------

Patients were retrospectively identified from a database of the Emory University Hospital (EUH) & Emory University Hospital Midtown (EUHM) cardiac electrophysiology labs from January 2003 to July 2008. The study cohort included all patients aged greater than or equal to 80 years old who underwent an initial implant or an upgrade to CRT, with or without an implantable cardioverter-defibrillator (ICD), (i.e., CRT-D or CRT-P). The control cohort consisted of 177 randomly selected patients \< 80 years old undergoing CRT implantation during the same time period. The decision to refer for CRT and the decision to implant a concomitant ICD were made by the primary cardiologist in conjunction with the implanting electrophysiologist. Although criteria for CRT implantation evolved during the study period, decisions regarding CRT implantation were made primarily based on evidence of inter-ventricular conduction delay as evidenced by prolonged QRS duration, or high degree right ventricular pacing, in conjunction with impaired LVEF and symptoms of HF. In some instances, echocardiographic evidence of inter-ventricular dyssynchrony was also used for assessing CRT candidacy.

Demographic data, baseline covariates and clinical history were obtained from review of medical records. Baseline QRS duration was measured during sinus rhythm for patients with native conduction and during pacing for patients with high burden right ventricular pacing as the indication for CRT. Certain baseline data were available for all octogenarian patients and controls whereas more detailed baseline data were only available for a subset of patients in both groups (41 out 96 octogenarians and 118 out of 177 controls). Patients for whom more detailed baseline data were not available were generally those implanted during the earlier years of the study cohort, such that electronic medical records were not available for review. Data on post-implant survival were obtained from review of medical records, routine device clinic follow-up and remote device monitoring. For patients whose vital status was not known, follow-up was censored at the date of last clinical contact.

Technical aspects of the CRT implant procedure, including positioning of the left ventricular lead, were performed at the discretion of the implanting physician. All left ventricular leads were implanted with a trans-venous approach via the coronary sinus. Device programming, including CRT parameters and ventricular tachyarrhythmia detection and therapy, was performed at the discretion of the implanting physician. Device follow-up, including in-office assessments and remote device monitoring, was performed through the EUH/EUHM arrhythmia center as clinically indicated. For patients presenting with ICD shocks, intracardiac electrogram adjudication for discrimination of appropriate from inappropriate therapies was performed through the arrhythmia center in conjunction with the implanting electrophysiologist, according to routine clinical protocol.

The protocol for this study was reviewed and approved by the Emory University Institutional Review Board.

2.2. Statistical analysis {#s2b}
-------------------------

The primary endpoint was all-cause mortality at 36 months after CRT. The time course of the primary endpoint, stratified by age ≥ or \< 80 years at CRT implant, was estimated by Kaplan-Meier time to first event curves and tested with the log-rank test. Secondary endpoints included the frequency of appropriate and inappropriate ICD shocks during follow-up.

Continuous variables are presented as mean ± SD and categorical data are summarized as frequencies and percentages. Comparisons across groups were performed using the Student\'s *t*-test, Chi-square test or Fisher\'s exact test, as appropriate. For all comparisons, *P* \< 0.05 was considered to be statistically significant. Analysis was performed using STATISTICA software (Statsoft, Inc., Tulsa, OK, USA).

3. Results {#s3}
==========

A total of 96 octogenarians underwent CRT implantation during the study period and were included as the study cohort. The control cohort included 177 patients \< 80 years old undergoing CRT implant at our institution during the same time frame. Baseline characteristics available for all patients in both cohorts are presented in the top portion of [Table 1](#jgc-11-03-180-t01){ref-type="table"} and more detailed baseline characteristics available for a subset of patients (41 out 96 octogenarians and 118 out of 177 controls) are presented in the bottom portion of [Table 1](#jgc-11-03-180-t01){ref-type="table"}. The mean age at CRT implant among octogenarians was 83 ± 2.9 years, compared to 60.1 ± 8.8 years in the control group (*P* \< 0.001). The percentage of male patients was similar in both groups (73% *vs*. 69%, *P* = NS) whereas baseline comorbidities including the presence of coronary artery disease (CAD) (74% *vs*. 37%) and hypertension (76% *vs*. 47%) were significantly more common among octogenarians (*P* \< 0.001 for both comparisons).

###### Baseline characteristics.

                                                  Cases (*n* = 96)         Controls (*n* = 177)        *P*
  ------------------------------------------- ------------------------ ---------------------------- ----------
  Age                                                83.1 ± 2.9                 60.1 ± 8.8           \< 0.001
  Male                                                70 (73)                    122 (69)             0.579
  LVEF                                             23.2% ± 10.5%              25.9% ± 15.9%           0.161
  QRS, ms                                           154.2 ± 22.6               154.0 ± 25.6           0.976
  CAD                                                 71 (74)                    65 (37)             \< 0.001
  HTN                                                 73 (76)                    83 (47)             \< 0.001
  Initial implant (*vs*. upgrade)                     56 (58)                    143 (81)            \< 0.001
  CRT-D (*vs*. CRT-P)                                 86 (90)                    159 (90)             0.834
                                               **\*Cases (*n* = 41)**   **\*Controls (*n* = 118)**  
  New York Heart Association Class                                                                  
   I                                                     0                        3 (3)               0.212
   II                                                  7 (17)                    25 (21)            
   III                                                34 (83)                    85 (72)            
  History of atrial fibrillation                      17 (41)                    27 (23)              0.027
  History of MI                                       21 (51)                    41 (35)              0.067
  History of PCI                                      13 (32)                    30 (25)              0.541
  History of CABG                                      6 (15)                    19 (16)              1.000
  End stage renal disease                              2 (5)                      7 (6)               1.000
  ICD implantation for secondary prevention            5 (12)                     10 (8)              0.537
  Medical therapy at time of CRT implant                                                            
   ACE-I/ARB                                          34 (83)                    98 (83)              1.000
   Beta blockers                                      34 (83)                    99 (84)              1.000
   Diuretics                                          35 (85)                    99 (84)              1.000
   Digoxin                                            10 (24)                    41 (35)              0.249
   Statins                                            22 (54)                    70 (59)              0.583
   Amiodarone                                          4 (10)                    19 (16)              0.442
   Aspirin                                            29 (71)                    77 (65)              0.569
   Warfarin                                           13 (32)                    43 (36)              0.705

\*Data only available for 41 out of 96 cases and 118 out of 177 controls. Data are presented as mean ± SD or *n* (%). ACE-I/ARB: angiotensin converting enzyme-inhibitor/angiotensin receptor blocker; CABG: coronary artery bypass grafting; CAD: coronary artery disease; CRT-D: cardiac resynchronization therapy-defibrillator; CRT-P: cardiac resynchronization therapy-pacemaker; HTN: hypertension; ICD: implantable cardioverter defibrillator; LVEF: left ventricle ejection fraction; MI: myocardial infarction; PCI: percutaneous coronary intervention.

Baseline LVEF (23.2% ± 10.5% *vs*. 25.9% ± 15.9%) and QRS duration (154.2 ± 22.6 ms *vs*. 154.0 ± 25.6 ms) were similar between groups. Octogenarians were more likely to undergo upgrade to CRT from pre-existing devices (42% *vs*. 19%, *P* \< 0.001) and 90% of patients in both groups were implanted with ICDs, without significant difference between octogenarians and controls.

Data on procedural and clinical outcomes are presented in [Table 2](#jgc-11-03-180-t02){ref-type="table"}. Acute procedural success was excellent in both groups with 99% of patients implanted successfully with LV leads without any major peri-procedural adverse events in either group. One patient in each group developed a significant pocket hematoma requiring intervention during the index hospitalization. During a mean follow-up of 4.27 ± 2.88 years, the frequency of patients receiving at least one ICD shock was lower among octogenarians (17%) than controls (33%, *P* = 0.011). Similarly, the frequency of patients receiving at least one appropriate ICD shock was also lower among octogenarians (14% *vs*. 27%, *P* = 0.024) whereas the frequency of inappropriate shocks was similar between groups (octogenarians 3% *vs*. controls 6%, *P* = N.S.).

The cumulative rate of all-cause mortality at 36 months estimated by Kaplan-Meier product limit estimates is presented in the [Figure](#jgc-11-03-180-g001){ref-type="fig"}. There was no significant difference in the time-dependent cumulative rate of all-cause mortality between octogenarians (15%) and controls (10%) at three years (*P* = 0.232).

4. Discussion {#s4}
=============

Despite the growing HF epidemic among elderly patients, there is a relative paucity of data-driven strategies for HF management in this population. Our data from a large single-center retrospective study suggest that among appropriately selected patients, survival among octogenarians following CRT implant is comparable to that among younger patients.

###### Procedural outcomes.

                                   Cases (n = 96)   Controls (*n* = 177)    *P*
  ------------------------------- ---------------- ---------------------- -------
  Acute LV lead implant success       95 (99)             175 (99)         0.542
  Hematoma                             1 (1)              1 (0.5)          1.000
  Shocks                                                                  
   All shocks                         16 (17)             58 (33)          0.011
   Appropriate                        13 (14)             48 (27)          0.024
   Inappropriate                       3 (3)               11 (6)          0.550

Data are presented as mean ± SD or *n* (%). LV: left ventricle.
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Furthermore, the prevalence of total and appropriate ICD shocks among octogenarians implanted with CRT-defibrillators was lower than that among younger counterparts with CRT-D devices, whereas the prevalence of inappropriate shocks was similar between groups.

Our data add to a limited body of literature reporting outcomes of CRT in elderly patients. In a retrospective, single-center series from the Mayo Clinic, survival over five years following CRT among 90 octogenarians was significantly worse than younger patients, although the difference in survival was no longer significant after adjusting for baseline covariates.[@b13] An important difference between our data and the series from the Mayo Clinic is that in our cohort, the frequency of concomitant defibrillator therapy was identical in octogenarians and younger controls (90% in both groups received CRT-D) whereas in the Mayo series, octogenarians were significantly less likely to receive CRT-D *vs*. CRT-P (78.9% CRT-D in octogenarians *vs*. 92% CRT-D in younger controls, *P* \< 0.001). The difference in all-cause mortality between octogenarians and younger controls in our study and the series from Mayo Clinic may be explained by the difference in prevalence of concomitant ICD therapy noted in the Mayo series. The impact of ICDs on CRT outcome in different age subgroups was also highlighted in a subgroup analysis from the multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy (MADIT-CRT) trial,[@b5] in which randomization to CRT with defibrillator was associated with a significant reduction in risk of HF or death (*vs*. defibrillator therapy alone) among patients ≥ 75 years old, whereas the benefit of CRT-D *vs*. ICD was attenuated in patients younger than 60.[@b14] However, it is important to note that in the smaller subgroup of octogenarians from MADIT-CRT, randomization to CRT-D *vs*. ICD was not associated with a significantly improved outcome, further highlighting the disparity of data on outcomes specifically among patients over the age of 80. Lastly, in a recently published ICD registry from Israel, recipients of CRT-D aged \> 75 years had similar rates of survival and appropriate ICD shocks compared to younger patients. Conversely, in ICD recipients without CRT, patients older than 75 years old had significantly worse survival.[@b15] These studies highlight the complex interactions noted between age and concomitant ICD therapy in assessing CRT outcomes among elderly patients.

The majority of CRT recipients in our study received concomitant ICD therapy and our results should be interpreted in this context. Relatively few octogenarians underwent CRT-P implantation precluding statistical analysis in this subgroup. However, previous studies have assessed outcomes among larger groups of octogenarians implanted with CRT-P devices. In two single center studies, crude mortality rates during a mean follow-up of 20 months[@b10] and 60 months[@b13] were significantly higher among octogenarians compared to younger counterparts. In both of these studies, octogenarians were significantly less likely to be implanted with defibrillators than the younger control cohorts. Although prior studies of ICD therapy have suggested that elderly patients likely benefit from primary prevention ICD therapy,[@b16],[@b17] in our study octogenarians were less likely to receive appropriate ICD therapy than younger patients. Also, in prior studies, no significant difference has been noted in incidence of appropriate device therapies between older and younger CRT-D recipients.[@b13],[@b15] Therefore, the observation in retrospective studies that elderly CRT-D recipients seem to fair better compared to younger controls than elderly CRT-P recipients is probably not related to the protective effects of ICD therapy *per se*. Rather, this observation is likely a reflection of the fact that elderly patients who are felt to have sufficiently good life expectancy to merit ICD implantation likely have better overall survival than elderly patients with symptomatic HF who may be felt to benefit from CRT but may not necessarily be felt to have sufficiently good life expectancy to merit concomitant ICD therapy. In this regard, our data reflect the immense importance of patient selection in determining which elderly patients are most likely to benefit from cardiac resynchronization, and CRT-D in particular.

4.1. Limitations {#s4a}
----------------

Several important limitations of our study should be noted. Most importantly, our data is retrospective and the decision to refer for CRT was not randomized but rather made at the discretion of the treating physicians. This clearly introduces a selection bias and limits the ability to extrapolate these findings to the general population of elderly patients with HF who might be CRT candidates. Furthermore, although prior studies have demonstrated comparable improvements in HF symptoms and quality of life among elderly patients undergoing CRT compared to younger counterparts, we do not have data on quality of life metrics which would also be particularly important considerations in making the decision to refer elderly patients for device implant.

4.2. Conclusion {#s4b}
---------------

In a single-center retrospective cohort, appropriately selected octogenarians undergoing CRT implantation, predominantly with concomitant ICD therapy, experienced similar rates of all-cause mortality during intermediate term follow-up (3 years) compared to younger CRT recipients. Although we are unable to comment on functional capacity and LVEF trends after CRT, our findings support the idea that with regard to overall survival, appropriate candidates for CRT should be offered this therapy even if they are of advanced age.
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